Cdc42 in podocytes plays a crucial role in insulin secretion by β-cells, which may provide a new therapeutic target to prevent the vicious cycle of β-cell dysfunction in T2DM. This evidence concerns the gene CDC42 and type 2 diabetes mellitus.